糖基化作为核酸疫苗设计的关键参数。
Glycosylation as a key parameter in the design of nucleic acid vaccines.
机构信息
Department of Biochemistry and Molecular Biology, Center for Molecular Medicine, The University of Georgia, Athens, Georgia, USA.
Department of Biochemistry and Molecular Biology, Center for Molecular Medicine, The University of Georgia, Athens, Georgia, USA.
出版信息
Curr Opin Struct Biol. 2022 Apr;73:102348. doi: 10.1016/j.sbi.2022.102348. Epub 2022 Mar 4.
Abstract
Vaccine-induced immunity is expected to target the native antigens expressed by the pathogens. Therefore, it is highly important to generate vaccine antigens that are immunologically indistinguishable from the native antigens. Nucleic acid vaccines, comprised of DNA, mRNA, or recombinant viral vector vaccines, introduce the genetic material encoding the antigenic protein for the host to express. Because these proteins will undergo host posttranslational modifications, host glycosylation can potentially alter the structure and immunological efficacy of the antigen. In this review, we discuss the potential impact of host protein glycosylation on the immune responses generated by nucleic acid vaccines against bacterial and viral pathogens.
摘要
疫苗诱导的免疫反应预计针对病原体表达的天然抗原。因此，生成在免疫学上与天然抗原无法区分的疫苗抗原非常重要。核酸疫苗包括 DNA、mRNA 或重组病毒载体疫苗，将编码抗原蛋白的遗传物质导入宿主以进行表达。由于这些蛋白将经历宿主翻译后修饰，宿主糖基化可能改变抗原的结构和免疫效力。在这篇综述中，我们讨论了宿主蛋白糖基化对核酸疫苗针对细菌和病毒病原体产生的免疫反应的潜在影响。
相似文献
1
Glycosylation as a key parameter in the design of nucleic acid vaccines.糖基化作为核酸疫苗设计的关键参数。
Curr Opin Struct Biol. 2022 Apr;73:102348. doi: 10.1016/j.sbi.2022.102348. Epub 2022 Mar 4.
2
Host protein glycosylation in nucleic acid vaccines as a potential hurdle in vaccine design for nonviral pathogens.核酸疫苗中宿主蛋白糖基化作为非病毒病原体疫苗设计的潜在障碍。
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1280-1282. doi: 10.1073/pnas.1916131117. Epub 2020 Jan 6.
3
Nucleic acid vaccines.核酸疫苗
Clin Microbiol Rev. 1995 Jul;8(3):406-10. doi: 10.1128/CMR.8.3.406.
4
Fish vaccine antigens produced or delivered by recombinant DNA technologies.通过重组DNA技术生产或递送的鱼类疫苗抗原。
Dev Biol Stand. 1997;90:267-77.
5
DNA-antiviral vaccines: new developments and approaches--a review.DNA抗病毒疫苗：新进展与方法——综述
Virus Genes. 1998;17(3):219-32. doi: 10.1023/a:1008013720032.
6
Immune response against viral infections and nucleic acid-based vaccines.针对病毒感染和基于核酸的疫苗的免疫反应。
Scand J Immunol. 2022 Dec;96(6):e13221. doi: 10.1111/sji.13221. Epub 2022 Oct 13.
7
Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity.认识疫苗中的翻译后修饰：增强免疫原性的一种途径。
J Cell Physiol. 2021 Dec;236(12):8020-8034. doi: 10.1002/jcp.30483. Epub 2021 Jun 25.
8
Impact of Protein Glycosylation on the Design of Viral Vaccines.蛋白质糖基化对病毒疫苗设计的影响。
Adv Biochem Eng Biotechnol. 2021;175:319-354. doi: 10.1007/10_2020_132.
9
Absence of an N-Linked Glycosylation Motif in the Glycoprotein of the Live-Attenuated Argentine Hemorrhagic Fever Vaccine, Candid #1, Results in Its Improper Processing, and Reduced Surface Expression.减毒活阿根廷出血热疫苗Candid #1糖蛋白中缺乏N-连接糖基化基序，导致其加工不当，表面表达减少。
Front Cell Infect Microbiol. 2017 Feb 6;7:20. doi: 10.3389/fcimb.2017.00020. eCollection 2017.
10
Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications.用于疫苗和免疫治疗应用的二十面体植物病毒基纳米颗粒的基因改造
Curr Protein Pept Sci. 2017 Aug 30;18(11):1141-1151. doi: 10.2174/1389203718666170424153109.
引用本文的文献
1
Future Sequon Finder - A novel approach for predicting future N-linked glycosylation sequon locations on viral surface proteins.未来糖基化位点查找器——一种预测病毒表面蛋白上未来N-糖基化位点位置的新方法。
PLoS One. 2025 Aug 14;20(8):e0328174. doi: 10.1371/journal.pone.0328174. eCollection 2025.
2
Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.新型戊型肝炎病毒疫苗变体的设计与分析以及两种选定候选疫苗在猪感染模型中的评估
Liver Int. 2025 Sep;45(9):e70246. doi: 10.1111/liv.70246.
3
Challenges and opportunities in mRNA vaccine development against bacteria.抗细菌mRNA疫苗开发中的挑战与机遇。
Nat Microbiol. 2025 Aug;10(8):1816-1828. doi: 10.1038/s41564-025-02070-z. Epub 2025 Jul 29.
4
Molecular mechanisms of immune evasion by host protein glycosylation of a bacterial immunogen used in nucleic acid vaccines.核酸疫苗中使用的细菌免疫原通过宿主蛋白糖基化实现免疫逃逸的分子机制。
bioRxiv. 2025 May 30:2025.05.29.656815. doi: 10.1101/2025.05.29.656815.
5
Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes.克里米亚-刚果出血热病毒糖蛋白复合物的工程与结构
Cell. 2025 Jan 23;188(2):303-315.e13. doi: 10.1016/j.cell.2024.11.008. Epub 2024 Dec 18.
6
Immunogenicity Analysis of Chikungunya Virus DNA Vaccine Based on Mutated Putative N-Linked Glycosylation Sites of the Envelope Protein.基于包膜蛋白假定的N-糖基化位点突变的基孔肯雅病毒DNA疫苗的免疫原性分析
Vaccines (Basel). 2024 Sep 26;12(10):1097. doi: 10.3390/vaccines12101097.
7
How Proteomics Can Inform Vaccine Design for Sexually Transmitted Infections.蛋白质组学如何为性传播感染的疫苗设计提供信息。
Sex Transm Dis. 2024 Oct 1;51(10):e36-e39. doi: 10.1097/OLQ.0000000000001986. Epub 2024 Jun 11.
8
Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.糖基化对病毒免疫原的免疫原性和抗原性的影响。
Biotechnol Adv. 2024 Jan-Feb;70:108283. doi: 10.1016/j.biotechadv.2023.108283. Epub 2023 Nov 14.
9
Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.糖基异质性是 HIV-1 中和作用中持久性部分的原因。
PLoS Pathog. 2023 Oct 30;19(10):e1011601. doi: 10.1371/journal.ppat.1011601. eCollection 2023 Oct.
10
Contemporaneous SARS-CoV-2-Neutralizing Antibodies Mediated by N-glycan Shields.由 N-聚糖盾牌介导的同时针对 SARS-CoV-2 的中和抗体。
Viruses. 2023 Oct 12;15(10):2079. doi: 10.3390/v15102079.
本文引用的文献
1
Current Progress in the Development of Zika Virus Vaccines.寨卡病毒疫苗研发的当前进展
Vaccines (Basel). 2021 Sep 9;9(9):1004. doi: 10.3390/vaccines9091004.
2
HIV and Messenger RNA (mRNA) Vaccine.艾滋病毒与信使核糖核酸（mRNA）疫苗。
Cureus. 2021 Jul 5;13(7):e16197. doi: 10.7759/cureus.16197. eCollection 2021 Jul.
3
Recent developments and strategies of Ebola virus vaccines.埃博拉病毒疫苗的最新进展和策略。
Curr Opin Pharmacol. 2021 Oct;60:46-53. doi: 10.1016/j.coph.2021.06.008. Epub 2021 Jul 27.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021.辉瑞-生物科技和莫德纳疫苗对≥65 岁住院成年人 COVID-19 的有效性-美国，2021 年 1 月至 3 月。
MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):674-679. doi: 10.15585/mmwr.mm7018e1.
5
A cross-neutralizing antibody between HIV-1 and influenza virus.HIV-1 和流感病毒之间的交叉中和抗体。
PLoS Pathog. 2021 Mar 22;17(3):e1009407. doi: 10.1371/journal.ppat.1009407. eCollection 2021 Mar.
6
The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines.科学依据在此：稳定基于病毒载体的新冠疫苗的关键考量因素
J Pharm Sci. 2021 Feb;110(2):627-634. doi: 10.1016/j.xphs.2020.11.015. Epub 2020 Nov 23.
7
Self-amplifying RNA vaccines for infectious diseases.用于传染病的自我扩增 RNA 疫苗。
Gene Ther. 2021 Apr;28(3-4):117-129. doi: 10.1038/s41434-020-00204-y. Epub 2020 Oct 22.
8
Visualization of the HIV-1 Env glycan shield across scales.HIV-1 包膜糖蛋白盾的多尺度可视化。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28014-28025. doi: 10.1073/pnas.2000260117. Epub 2020 Oct 22.
9
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.糖基化 SARS-CoV-2 刺突蛋白与人血管紧张素转换酶 2 受体的病毒-受体相互作用。
Cell Host Microbe. 2020 Oct 7;28(4):586-601.e6. doi: 10.1016/j.chom.2020.08.004. Epub 2020 Aug 24.
10
Interferon-α alters host glycosylation machinery during treated HIV infection.干扰素-α在治疗 HIV 感染期间改变宿主糖基化机制。
EBioMedicine. 2020 Sep;59:102945. doi: 10.1016/j.ebiom.2020.102945. Epub 2020 Aug 19.
Zotero 插件